Exact Mass: 619.3475484
Exact Mass Matches: 619.3475484
Found 212 metabolites which its exact mass value is equals to given mass value 619.3475484,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Glycylalanylprolylmethionylphenylalanylvalinamide
Glycylalanylprolylmethionylphenylalanylvalinamide is found in mollusks. Glycylalanylprolylmethionylphenylalanylvalinamide is isolated from the pedal ganglion of Mytilus edulis (blue mussel). Isolated from the pedal ganglion of Mytilus edulis (blue mussel). Glycylalanylprolylmethionylphenylalanylvalinamide is found in mollusks.
N-((Hexahydro-1-azepinyl)carbonyl)-leucyl(1-methyl)-tryptophyl-tryptophan
PC(2:0/20:3(8Z,11Z,14Z)-2OH(5,6))
PC(2:0/20:3(8Z,11Z,14Z)-2OH(5,6)) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/20:3(8Z,11Z,14Z)-2OH(5,6)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 5,6-dihydroxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).
PC(20:3(8Z,11Z,14Z)-2OH(5,6)/2:0)
PC(20:3(8Z,11Z,14Z)-2OH(5,6)/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(20:3(8Z,11Z,14Z)-2OH(5,6)/2:0), in particular, consists of one chain of one 5,6-dihydroxyeicosatrienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).
2-(2-{3-[2-(1,1-dimethyl-allyl)-indol-3-ylmethylene]-11-methyl-2,5-dioxo-1,4-diaza-spiro[5.5]undec-9-en-8-yl}-vinyl)-3,6-dihydroxy-5-(3-methyl-but-2-enyl)-benzaldehyde|Cryptoechinulin D|Kryptoechinulin D
Cys Arg Arg Trp
C26H41N11O5S (619.3012696000001)
Cys Arg Trp Arg
C26H41N11O5S (619.3012696000001)
Cys Trp Arg Arg
C26H41N11O5S (619.3012696000001)
Phe Lys Tyr Tyr
Phe Tyr Lys Tyr
Phe Tyr Tyr Lys
Lys Phe Tyr Tyr
Lys Met Arg Trp
Lys Met Trp Arg
Lys Arg Met Trp
Lys Arg Trp Met
Lys Thr Trp Trp
C32H41N7O6 (619.3118165999999)
Lys Trp Met Arg
Lys Trp Arg Met
Lys Trp Thr Trp
C32H41N7O6 (619.3118165999999)
Lys Trp Trp Thr
C32H41N7O6 (619.3118165999999)
Lys Tyr Phe Tyr
Lys Tyr Tyr Phe
Met Lys Arg Trp
Met Lys Trp Arg
Met Arg Lys Trp
Met Arg Trp Lys
Met Trp Lys Arg
Met Trp Arg Lys
Arg Cys Arg Trp
C26H41N11O5S (619.3012696000001)
Arg Cys Trp Arg
C26H41N11O5S (619.3012696000001)
Arg Lys Met Trp
Arg Lys Trp Met
Arg Met Lys Trp
Arg Met Trp Lys
Arg Arg Cys Trp
C26H41N11O5S (619.3012696000001)
Arg Arg Trp Cys
C26H41N11O5S (619.3012696000001)
Arg Trp Cys Arg
C26H41N11O5S (619.3012696000001)
Arg Trp Lys Met
Arg Trp Met Lys
Arg Trp Arg Cys
C26H41N11O5S (619.3012696000001)
Thr Lys Trp Trp
C32H41N7O6 (619.3118165999999)
Thr Trp Lys Trp
C32H41N7O6 (619.3118165999999)
Thr Trp Trp Lys
C32H41N7O6 (619.3118165999999)
Trp Cys Arg Arg
C26H41N11O5S (619.3012696000001)
Trp Lys Met Arg
Trp Lys Arg Met
Trp Lys Thr Trp
C32H41N7O6 (619.3118165999999)
Trp Lys Trp Thr
C32H41N7O6 (619.3118165999999)
Trp Met Lys Arg
Trp Met Arg Lys
Trp Arg Cys Arg
C26H41N11O5S (619.3012696000001)
Trp Arg Lys Met
Trp Arg Met Lys
Trp Arg Arg Cys
C26H41N11O5S (619.3012696000001)
Trp Thr Lys Trp
C32H41N7O6 (619.3118165999999)
Trp Thr Trp Lys
C32H41N7O6 (619.3118165999999)
Trp Trp Lys Thr
C32H41N7O6 (619.3118165999999)
Trp Trp Thr Lys
C32H41N7O6 (619.3118165999999)
Tyr Phe Lys Tyr
Tyr Phe Tyr Lys
Tyr Lys Phe Tyr
Tyr Lys Tyr Phe
Tyr Tyr Phe Lys
Tyr Tyr Lys Phe
Glycylalanylprolylmethionylphenylalanylvalinamide
Osteostatin (1-5) (human, bovine, dog, horse, mouse, rabbit, rat) trifluoroacetate salt
C27H41N9O8 (619.3077946000001)
N-((Hexahydro-1-azepinyl)carbonyl)-leucyl(1-methyl)-tryptophyl-tryptophan
(2S,3R,6S,8S,13S,16S)-9,13-dihydroxy-8-(2-hydroxypropan-2-yl)-2,3,23,23,25,25-hexamethyl-7,11,24-trioxa-32-azanonacyclo[16.14.0.02,16.03,13.06,12.010,12.019,31.020,28.022,26]dotriaconta-1(18),19(31),20(28),29-tetraen-27-one
1-[[(2R,3S)-8-[[(cyclohexylamino)-oxomethyl]amino]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea
1-[[(2S,3S)-10-[[(cyclohexylamino)-oxomethyl]amino]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea
1-[[(2S,3R)-10-[[(cyclohexylamino)-oxomethyl]amino]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea
N-[(3R,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(propyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methoxybenzenesulfonamide
3-cyclohexyl-1-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-10-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methylurea
N-[(3R,9S,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(propyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methoxybenzenesulfonamide
N-[(3S,9S,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(propyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methoxybenzenesulfonamide
N-[(3S,9S,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(propyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methoxybenzenesulfonamide
N-[(3R,9S,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(propyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methoxybenzenesulfonamide
3-cyclohexyl-1-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-10-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methylurea
N-[(3R,9S,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(propyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methoxybenzenesulfonamide
1-[[(2R,3R)-8-[[(cyclohexylamino)-oxomethyl]amino]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea
1-[[(2R,3S)-10-[[(cyclohexylamino)-oxomethyl]amino]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea
N-[(3S,9S,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-fluorobenzenesulfonamide
C32H46FN3O6S (619.3091188000001)
1-[[(2S,3S)-10-[[(cyclohexylamino)-oxomethyl]amino]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea
1-[[(2R,3R)-10-[[(cyclohexylamino)-oxomethyl]amino]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea
N-[(3R,9R,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-fluorobenzenesulfonamide
C32H46FN3O6S (619.3091188000001)
1-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-9-[[(4-methoxyanilino)-oxomethyl]amino]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-3-(4-methoxyphenyl)-1-methylurea
N-[(3S,9R,10R)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-fluorobenzenesulfonamide
C32H46FN3O6S (619.3091188000001)
N-[(3S,9R,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-fluorobenzenesulfonamide
C32H46FN3O6S (619.3091188000001)
N-[(3R,9S,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-fluorobenzenesulfonamide
C32H46FN3O6S (619.3091188000001)
N-[(3R,9S,10R)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-fluorobenzenesulfonamide
C32H46FN3O6S (619.3091188000001)
N-[(3S,9S,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-fluorobenzenesulfonamide
C32H46FN3O6S (619.3091188000001)
N-[(3R,9R,10R)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-fluorobenzenesulfonamide
C32H46FN3O6S (619.3091188000001)
2-amino-3-[[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-heptanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
2-amino-3-[[3-hexanoyloxy-2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
2-amino-3-[[3-butanoyloxy-2-[(11Z,14Z)-icosa-11,14-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
2-amino-3-[[2-[(11Z,14Z)-henicosa-11,14-dienoyl]oxy-3-propanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
2-amino-3-[[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-octanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
2-amino-3-[hydroxy-[2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxy-3-pentanoyloxypropoxy]phosphoryl]oxypropanoic acid
3-[[3-acetyloxy-2-[(13Z,16Z)-docosa-13,16-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxy-2-aminopropanoic acid
N-[(4E,8E,12E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxypentadeca-4,8,12-trien-2-yl]acetamide
N-[(4E,8E,12E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxytetradeca-4,8,12-trien-2-yl]propanamide
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate
Cyclo(RGDyK)
C27H41N9O8 (619.3077946000001)
Cyclo(RGDyK) is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.
(9z)-n-({[(2r,3r,4r,5r)-2-[(1s)-1,2-dihydroxyethyl]-4,5-dihydroxy-6-(9h-purin-6-ylamino)oxan-3-yl]-c-hydroxycarbonimidoyl}methyl)-14-methylpentadec-9-enimidic acid
C30H49N7O7 (619.3693284000001)
2-[(1e)-2-[(3z,6r,8r,11s)-2,5-dihydroxy-11-methyl-3-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-1,4-diazaspiro[5.5]undeca-1,4,9-trien-8-yl]ethenyl]-3,6-dihydroxy-5-(3-methylbut-2-en-1-yl)benzaldehyde
arsenic selenide
{"Ingredient_id": "HBIN016906","Ingredient_name": "arsenic selenide","Alias": "NA","Ingredient_formula": "As4Se4","Ingredient_Smile": "[As](=[Se])[Se][As]=[Se]","Ingredient_weight": "615.53","OB_score": "NA","CAS_id": "52126-83-7","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "6627","PubChem_id": "14772","DrugBank_id": "NA"}
(2s,3r,6s,8s,9r,12s,13s,16s,22r,26r)-9,13-dihydroxy-8-(2-hydroxypropan-2-yl)-2,3,23,23,25,25-hexamethyl-7,11,24-trioxa-32-azanonacyclo[16.14.0.0²,¹⁶.0³,¹³.0⁶,¹².0¹⁰,¹².0¹⁹,³¹.0²⁰,²⁸.0²²,²⁶]dotriaconta-1(18),19,28,30-tetraen-27-one
4-{[6-({15-[(1-carboxyethyl)-c-hydroxycarbonimidoyl]-2-methylpentadecan-3-yl}oxy)-3,4,5-trihydroxyoxan-2-yl]methoxy}-4-oxobutanoic acid
(2s,3r,6s,8s,9r,10r,12r,13s,16s,22s,26r)-9,13-dihydroxy-8-(2-hydroxypropan-2-yl)-2,3,23,23,25,25-hexamethyl-7,11,24-trioxa-32-azanonacyclo[16.14.0.0²,¹⁶.0³,¹³.0⁶,¹².0¹⁰,¹².0¹⁹,³¹.0²⁰,²⁸.0²²,²⁶]dotriaconta-1(18),19,28,30-tetraen-27-one
3-[hydroxy({5-[(1-hydroxy-3-{hydroxy[5-({1-hydroxy-3-[hydroxy(5-hydroxypentyl)carbamoyl]propylidene}amino)pentyl]carbamoyl}propylidene)amino]pentyl})carbamoyl]propanoic acid
(2s,3r,6s,8s,9r,12s,13s,16s,22s,26s)-9,13-dihydroxy-8-(2-hydroxypropan-2-yl)-2,3,23,23,25,25-hexamethyl-7,11,24-trioxa-32-azanonacyclo[16.14.0.0²,¹⁶.0³,¹³.0⁶,¹².0¹⁰,¹².0¹⁹,³¹.0²⁰,²⁸.0²²,²⁶]dotriaconta-1(18),19,28,30-tetraen-27-one
(2s,3r,6s,8s,9r,12s,13s,16s,22s,26r)-9,13-dihydroxy-8-(2-hydroxypropan-2-yl)-2,3,23,23,25,25-hexamethyl-7,11,24-trioxa-32-azanonacyclo[16.14.0.0²,¹⁶.0³,¹³.0⁶,¹².0¹⁰,¹².0¹⁹,³¹.0²⁰,²⁸.0²²,²⁶]dotriaconta-1(18),19,28,30-tetraen-27-one
n-(1-{10-benzyl-8,11-dihydroxy-16-methoxy-2-oxa-6,9,12-triazatricyclo[13.3.1.0³,⁷]nonadeca-1(18),8,11,13,15(19),16-hexaen-6-yl}-3-methyl-1-oxobutan-2-yl)-2-(n-methylformamido)propanimidic acid
(2s,3r,6s,8s,13s,16s)-9,13-dihydroxy-8-(2-hydroxypropan-2-yl)-2,3,23,23,25,25-hexamethyl-7,11,24-trioxa-32-azanonacyclo[16.14.0.0²,¹⁶.0³,¹³.0⁶,¹².0¹⁰,¹².0¹⁹,³¹.0²⁰,²⁸.0²²,²⁶]dotriaconta-1(18),19,28,30-tetraen-27-one
2,5-dihydroxy-6-[2-(5-hydroxy-11-methyl-3-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-2-oxo-1,4-diazaspiro[5.5]undeca-4,9-dien-8-yl)ethenyl]-3-(3-methylbut-2-en-1-yl)benzaldehyde
9,15-dibenzyl-5,11,14-trihydroxy-3,6,12-triisopropyl-1,7-dimethyl-1,4,7,10,13-pentaazacyclopentadeca-4,10,13-triene-2,8-dione
C35H49N5O5 (619.3733503999999)
9,13-dihydroxy-8-(2-hydroxypropan-2-yl)-2,3,23,23,25,25-hexamethyl-7,11,24-trioxa-32-azanonacyclo[16.14.0.0²,¹⁶.0³,¹³.0⁶,¹².0¹⁰,¹².0¹⁹,³¹.0²⁰,²⁸.0²²,²⁶]dotriaconta-1(18),19,28,30-tetraen-27-one
4-{[(2r,3s,4s,5r,6r)-6-{[(3r)-15-{[(1s)-1-carboxyethyl]-c-hydroxycarbonimidoyl}-2-methylpentadecan-3-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methoxy}-4-oxobutanoic acid
(3s,6s,9s,12s,15s)-9,15-dibenzyl-5,11,14-trihydroxy-3,6,12-triisopropyl-1,7-dimethyl-1,4,7,10,13-pentaazacyclopentadeca-4,10,13-triene-2,8-dione
C35H49N5O5 (619.3733503999999)
(3s,6s,9s,12s,15s)-6,9-dibenzyl-5,11,14-trihydroxy-3,12,15-triisopropyl-1,7-dimethyl-1,4,7,10,13-pentaazacyclopentadeca-4,10,13-triene-2,8-dione
C35H49N5O5 (619.3733503999999)
3,6-dibenzyl-12-isopropyl-9,15-bis(2-methylpropyl)-1,4,7,10,13-pentaazacyclopentadeca-1,4,7,10,13-pentaene-2,5,8,11,14-pentol
C35H49N5O5 (619.3733503999999)
n-({[2-(1,2-dihydroxyethyl)-4,5-dihydroxy-6-(9h-purin-6-ylamino)oxan-3-yl]-c-hydroxycarbonimidoyl}methyl)-14-methylpentadec-9-enimidic acid
C30H49N7O7 (619.3693284000001)
6,9-dibenzyl-5,11,14-trihydroxy-3,12,15-triisopropyl-1,7-dimethyl-1,4,7,10,13-pentaazacyclopentadeca-4,10,13-triene-2,8-dione
C35H49N5O5 (619.3733503999999)
(3r,6r,9r,12r,15r)-3,6-dibenzyl-12-isopropyl-9,15-bis(2-methylpropyl)-1,4,7,10,13-pentaazacyclopentadeca-1,4,7,10,13-pentaene-2,5,8,11,14-pentol
C35H49N5O5 (619.3733503999999)